DDDetlev Drenckhahn

Detlev Drenckhahn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Detlev Drenckhahn has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Athina Efthymiadis

    University of Würzburg, Institute of Anatomy and Cell Biology, Koellikerstr. 6, D-97070 Würzburg, Germany

    2 shared publications
  • Jens Waschke

    Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany

    2 shared publications
  • Wolfgang-Moritz Heupel

    University of Würzburg, Institute of Anatomy and Cell Biology, Koellikerstr. 6, D-97070 Würzburg, Germany

    2 shared publications
  • Enno Schmidt

    Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany

    1 shared publication
  • Nicolas Schlegel

    University of Würzburg, Institute of Anatomy and Cell Biology, Koellikerstr. 6, D-97070 Würzburg, Germany

    1 shared publication
  • Thomas Müller

    University of Würzburg, Department of Botany I, Julius-von-Sachs-Platz 2, D-97082 Würzburg, Germany

    1 shared publication

Latest Publications

  • Open Access

    Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo

    by Wolfgang-Moritz Heupel, Athina Efthymiadis, Nicolas Schlegel, Thomas Müller, Yvonne Baumer, Werner Baumgartner, Detlev Drenckhahn, Jens Waschke

    Inflammatory stimuli result in vascular leakage with potentially life threatening consequences. As a key barrier component, loss of vascular endothelial (VE-) cadherin-mediated adhesion often precedes endothelial breakdown. This study aimed to stabilize VE-cadherin transinteraction and endothelial barrier function using peptides targeting the VE-cadherin adhesive interface. After modelling the transinteracting VE-cadherin structure, an inhibiting single peptide (SP) against a VE-cadherin binding pocket was selected, which specifically blocked VE-cadherin transinteraction as analyzed by single molecule atomic force microscopy (AFM). The tandem peptide (TP) consisting of two SP sequences in tandem was designed to strengthen VE-cadherin adhesion by simultaneously binding and cross-bridging two interacting cadherin molecules. Indeed, in AFM experiments TP specifically rendered VE-cadherin transinteraction resistant against an inhibitory monoclonal antibody. Moreover, TP reduced VE-cadherin lateral mobility and enhanced binding of VE-cadherin-coated microbeads to cultured endothelial cells, but acted independently of the actin cytoskeleton. TP also stabilized endothelial barrier properties against the Ca2+ ionophore A23187 and the inhibitory antibody. Finally, TP abolished endothelial permeability increase induced by tumour necrosis factor-α in microperfused venules in vivo. Stabilization of VE-cadherin adhesion by cross-bridging peptides may therefore be a novel therapeutic approach for the treatment of vascular hyperpermeability.


  • Open Access

    Peptides Targeting the Desmoglein 3 Adhesive Interface Prevent Autoantibody-induced Acantholysis in Pemphigus

    by Wolfgang-Moritz Heupel, Thomas Müller, Athina Efthymiadis, Enno Schmidt, Detlev Drenckhahn, Jens Waschke